Astilbin combined with lipopolysaccharide induces IL-10-producing regulatory B cells via the STAT3 signalling pathway

Yemin Xu,Keyan Wu,Sen Han,Shizhen Ding,Guotao Lu,Zhijie Lin,Yu Zhang,Weiming Xiao,Weijuan Gong,Yanbing Ding,Bin Deng
DOI: https://doi.org/10.1016/j.biopha.2020.110450
2020-09-01
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objectives</h3><p>Astilbin exerts immunoregulatory activities and plays anti-inflammatory effects in inflammation-associated diseases. IL-10-producing B cells are the major subset of regulatory B cells (Bregs) and inhibit inflammation and autoimmune diseases. This study aimed to analyse the inducing effect of astilbin on Bregs and investigate the involved molecular mechanisms.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>The frequencies and activities of IL-10-producing Bregs were observed using the co-treatment of astilbin and lipopolysaccharide (LPS) ex vivo. The protective effect of astilbin/LPS-induced Bregs on dextran sulphate sodium (DSS)-induced colitis was confirmed in vivo. The molecular signalling events of Breg induction were checked via Western blot. CD40<sup>−/−</sup> and toll-like receptor (TLR) 4<sup>−/−</sup> B cells were treated with astilbin/LPS to determine the modulatory role of CD40 or TLR4 on astilbin/LPS-induced Bregs.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Although astilbin alone could not affect Bregs, the co-treatment of astilbin and LPS remarkably induced CD19<sup>+</sup> CD1d<sup>hi</sup> and CD19<sup>+</sup> TIM-1<sup>+</sup> cells which produced IL-10 ex vivo. Colonic CD19<sup>+</sup> CD1d<sup>hi</sup> and CD19<sup>+</sup> TIM-1<sup>+</sup> cells were also increased in astilbin-treated mice with DSS-induced colitis. The adoptive transfer of CD19<sup>+</sup> TIM-1<sup>+</sup> cells pre-induced by astilbin/LPS directly suppressed the progression of DSS-induced colitis. Combined astilbin and LPS stimulated the STAT3 activation of CD19<sup>+</sup> TIM-1<sup>+</sup> cells but had no effects on SOCS3, AKT, NF-κB, Erk, JNK nor P38. Inhibiting the STAT3 phosphorylation of CD19<sup>+</sup> TIM-1<sup>+</sup> cells abolished Breg induction by astilbin/LPS. Furthermore, Breg induction was weakened in CD40<sup>−/−</sup> B cells with the decrease in STAT3 activation, but had disappeared in TLR4<sup>−/−</sup> B cells with no STAT3 activation, thereby confirming the indispensable role of TLR4 signalling in the induction of IL-10-producing Bregs.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>This study reports the new immunoregulatory role of astilbin for promoting IL-10-producing B cells and suggests the possible use of astilbin in the therapy of inflammatory diseases.</p>
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?